In situ quantification of endothelial cell damage caused by iodinated contrast media using a rat vena cava model

2012 ◽  
Vol 81 (5) ◽  
pp. 879-884 ◽  
Author(s):  
Natsuko Tsuda
Keyword(s):  
Endothelial Cell ◽  
Contrast Media ◽  
Cell Damage ◽  
Vena Cava ◽  
Iodinated Contrast Media ◽  
Endothelial Cell Damage ◽  
Iodinated Contrast ◽  
Rat Vena Cava

Red light has the capacity to blunt corneal endothelial cell damage in situ.

2014 ◽  
Vol 92 ◽  
pp. 0-0 ◽  
Author(s):  
C NÚÑEZ ÄLVAREZ ◽  
S OLMO-AGUADO ◽  
J MERAYO-LLOVES ◽  
NN OSBORNE
Keyword(s):  
Endothelial Cell ◽  
Cell Damage ◽  
Red Light ◽  
Corneal Endothelial Cell ◽  
Endothelial Cell Damage

Prostacyclic production in rabbit arteries in situ: Inhibition by arachidonic acid-induced endothelial cell damage or by low-dose aspirin

1981 ◽  
Vol 21 (4) ◽  
pp. 655-666 ◽  
Author(s):  
Carol Ingerman-Wojenski ◽  
Melvin J. Silver ◽  
J.Bryan Smith ◽  
Mark Nissenbaum ◽  
Albert W. Sedar
Keyword(s):  
Arachidonic Acid ◽  
Endothelial Cell ◽  
Low Dose ◽  
Cell Damage ◽  
Endothelial Cell Damage ◽  
Dose Aspirin ◽  
Low Dose Aspirin

Development of polyclonal and monoclonal antibodies to iodinated contrast media

1988 ◽  
Vol 29 (6) ◽  
pp. 737-740 ◽  
Author(s):  
R. L. Siegle ◽  
W. L. McGuire ◽  
J. E. Peters
Keyword(s):  
Monoclonal Antibodies ◽  
Contrast Media ◽  
Iodinated Contrast Media ◽  
Iodinated Contrast

Chemistry of Iodinated Contrast Media (ICM): A Minireview

2020 ◽  
Vol 17 ◽  
Author(s):  
Maithili Pramod Joshi ◽  
Ameya Chaudhari ◽  
Prashant S. Kharkar ◽  
Shreerang V. Joshi
Keyword(s):  
Adverse Effects ◽  
Contrast Media ◽  
Aqueous Solubility ◽  
Synthetic Methods ◽  
Essential Medicines ◽  
World Health ◽  
Iodinated Contrast Media ◽  
Environmental Aspects ◽  
Iodinated Contrast ◽  
Health Organization

: Historically, the use of Iodinated Contrast Media (ICM) for diagnostic purposes, particularly radiography and computed tomography (CT), is well-known. Many of the ICM are included in the World Health Organization (WHO)’s List of Essential Medicines. Depending on the chemotype and the presence of ionizable functional group(s), the ICM are categorized in the ionic/nonionic monomers/dimers. The lipophilicity, aqueous solubility, viscosity and osmolality are major characteristics dictating their use for one procedure versus the other. Over last several decades, substantial advancement occurred in the design and development of novel ICM, solely to reduce their propensity to cause adverse effects. Given the nature of their acute usage, some of the agents with appreciable toxicity are still used. Understanding their chemistry aspects is crucial to appreciate, acknowledge and justify the usage of these extremely important torch-bearers of diagnostic agent’s class. The present review article presents an in-depth overview of the synthetic methods, therapeutic indications, potential adverse effects along with the commercial and environmental aspects of ICM. The safety and tolerability of these agents is a field that has gained significant importance, which is given due importance in the discussion.

scholarly journals Pharmacologic and non-pharmacologic interventions to prevent hypersensitivity reactions of non-ionic iodinated contrast media: a systematic review protocol

BMJ Open ◽  
2020 ◽  
Vol 10 (3) ◽  
pp. e033023
Author(s):  
Hiroyasu Umakoshi ◽  
Takashi Nihashi ◽  
Hironori Shimamoto ◽  
Takehiro Yamada ◽  
Hiroaki Ishiguchi ◽  
...  
Keyword(s):  
Contrast Media ◽  
Assessment Tools ◽  
Average Risk ◽  
Cochrane Central Register ◽  
Hypersensitivity Reactions ◽  
Iodinated Contrast Media ◽  
Preventive Interventions ◽  
Validity Assessment ◽  
Iodinated Contrast ◽  
Standard Design

IntroductionIodinated contrast media are commonly used in medical imaging and can cause hypersensitivity reactions, including rare but severe life-threatening reactions. Although several prophylactic approaches have been proposed for severe reactions, their effects remain unclear. Therefore, we aim to review systematically the preventive effects of pharmacologic and non-pharmacologic interventions and predictors of acute, hypersensitivity reactions.Methods and analysisWe will search the PubMed, EMBASE and Cochrane Central Register of Controlled Trials databases from 1 January 1990 through 31 December 2019 and will examine the bibliographies of eligible studies, pertinent review articles and clinical practice guidelines. We will include prospective and retrospective studies of any design that evaluated the effects of pharmacological and non-pharmacological preventive interventions for adverse reactions of non-ionic iodinated contrast media. Two assessors will independently extract the characteristics of the study and intervention and the quantitative results. Two independent reviewers will assess the risk of bias using standard design-specific validity assessment tools. The primary outcome will be reduction in acute contrast media-induced hypersensitivity reactions. The secondary outcomes will include characteristics associated with the development of contrast media-induced acute hypersensitivity reactions, and adverse events associated with specific preventive interventions. Unique premedication regimens (eg, dose, drug and duration) and non-pharmacological strategies will be analysed separately. Average-risk and high-risk patients will be considered separately. A meta-analysis will be performed if appropriate.Ethics and disseminationEthics approval is not applicable, as this will be a secondary analysis of publicly available data. The results of the analysis will be submitted for publication in a peer reviewed journal.PROSPERO registration numberCRD42019134003

Fidelity of Electronic Documentation for Reactions Prompting Premedication to Iodinated Contrast Media

2021 ◽  
Author(s):  
Lakshmi Ananthakrishnan ◽  
Daniel T. Parrott ◽  
Nathan Mielke ◽  
Yin Xi ◽  
Matthew S. Davenport
Keyword(s):  
Contrast Media ◽  
Iodinated Contrast Media ◽  
Electronic Documentation ◽  
Iodinated Contrast
Sign in / Sign up

Export Citation Format

Share Document